Development asset linked to Sun Yat-sen University in public FDA and regional records.
pharma · Chronic Hepatitis B
Sun Yat-sen University
Third Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
3,680 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Employees
- 3,680
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Sun Yat-sen University pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sun Yat-sen University drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
peginterferon alfa-2b
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist